EnVivo Pharmaceuticals, Inc. to Present Phase 2b Clinical Data of Lead Program in Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2012
Published: Jun 13, 2012
WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer’s disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia. The data have been selected for oral presentation as part of the conference’s “Late Breaking Novel Therapeutics” session, being held Wednesday, July 18, 2012 from 3:30 to 5 p.m. The data presentation will also be highlighted in an Alzheimer’s Association news briefing at the conference on Wednesday, July 18, 2012 from 7:30 to 8:30 a.m.